Search

everythinglearnresearchcommunity

for

Search:↓

Men with early male pattern baldness (MPB) may have hormonal abnormalities similar to those in women with PCOS. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

A user is planning to get extensive blood tests before starting Finasteride and is seeking advice on which tests are necessary. They are concerned about the cost and potential redundancy of some tests.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

Someone's brother tried Platelet-rich plasma (PRP) for hair loss; it had minimal effect on hair but improved skin appearance. Microneedling at home was suggested as a more sustainable alternative.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

The conversation warns about taking information on pyrilutamide with skepticism, suggesting that many may not have the genuine product. It advises to wait for FDA approval for reliable information.

HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.

A user is considering ordering topical finasteride with castor and rosemary oil from a Turkish pharmacy. They are debating whether to include the oils or use only PG and ethanol as the carrier.

User TH1RT33N_DR34M shares that MinoxidilMax plans to make topical Procyanidin B2 within a month. Users discuss the legitimacy of the product, quality control, and potential results from using it for hair loss.

GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.

The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

A bodybuilder discusses homebrewing Minoxidil and RU58841 using propylene glycol or MCT. They inquire about the feasibility and potential risks of these methods.

The conversation is about the correct way to do microneedling for hair loss, with some users suggesting the user is pressing too hard and causing too much bleeding, while others think the amount of blood is fine. Specific treatments mentioned include microneedling, with advice to disinfect the roller and possibly use a shorter needle length.

Clascoterone powder is now available, but it's expensive and not widely discussed due to past ineffective results at higher concentrations. Users are skeptical about its effectiveness and are seeking reliable sources.

The conversation discusses hair thinning potentially linked to gut health issues and suggests biotin as a possible treatment. It also mentions that hair thinning could be due to male pattern baldness (MPB).

The conversation discusses the effects of B5 (Pantothenic acid), B7 (Biotin), and B12 on hair loss. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The user is experiencing significant hair shedding and suspects it may be due to low serum ferritin levels rather than worsening androgenetic alopecia. They have resumed iron supplementation and are seeking additional solutions to address the shedding.

A user experienced severe scalp itching with MPB and found Nizoral ineffective. A doctor diagnosed seborrheic eczema and prescribed Betacap, which relieved the itching.

Hair loss itch is caused by DHT attacking follicles and stimulating nerves. Finasteride users who respond well don't experience this itch.

The conversation discusses the variability in effectiveness of medications, including finasteride, and questions whether different manufacturers impact results. The user suggests sharing successful brands to help others identify effective options.

The conversation is about sourcing Latanoprost for hair loss treatment. Users discuss potential sources and the difficulty of obtaining a prescription.

The conversation is about whether castor oil can be effectively used alone after microneedling without a penetration enhancer like DMSO or ethanol. The user believes microneedling-induced wounds might be enough for absorption.

The conversation is about a potential new hair loss treatment called Breezula CB-03-01. Users are discussing updates on its development and sharing personal experiences with making or using it.

A mixture of MSM, kombucha, and black tea was applied topically for hair growth in mice. The conversation suggests skepticism about translating these results to humans.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

JW0061 shows superior hair growth results compared to existing treatments, with significant increases in hair follicles. The Wnt/β-catenin pathway is crucial for hair growth, and JW0061 activates this pathway effectively.